文献速递类风湿关节炎脊柱关节炎

糖皮质激素和肿瘤坏死因子抑制剂通过上调淋巴细胞活化基因-3发挥滑膜炎症新型抑制通路:一项离体研究

A novel inhibitory pathway of synovial inflammation exerted by glucocorticoids and tumour necrosis factor inhibitors via lymphocyte activation gene-3 up-regulation: an ex vivo study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该离体研究将银屑病关节炎(PsA)和类风湿关节炎(RA)患者的滑液单核细胞、骨关节炎(OA)患者的滑液细胞及健康供者外周血单核细胞与糖皮质激素、糖皮质激素受体拮抗剂RU486、甲氨蝶呤和生物制剂共培养,发现糖皮质激素和TNF抑制剂可上调CD14+LAG-3+细胞,且糖皮质激素对细胞生长的抑制与CD14+LAG-3+细胞上调相关。

要点

  • 糖皮质激素在PsA中抑制滑液单核细胞生长并显著上调CD14+LAG-3+细胞,但不影响CD3+LAG-3+和CD14+PD-1+细胞。
  • 英夫利西单抗和依那西普上调CD14+LAG-3+细胞,而IL-12/23抑制剂无此作用;甲氨蝶呤对CD14+LAG-3+细胞无影响。
  • RU486剂量依赖性抑制糖皮质激素诱导的CD14+LAG-3+细胞上调,但对英夫利西单抗共培养无显著影响。

核心结论

  • 该研究提出糖皮质激素和TNF抑制剂通过上调滑膜细胞和外周血单核细胞中LAG-3介导的新型调节机制。
  • LAG-3调控可能成为开发炎症性关节炎新型疗法的有前景靶点。

研究设计与样本

  • 离体研究:PsA患者滑液单核细胞(n=26)、RA患者滑液单核细胞(n=13)、OA患者滑液细胞(n=5)及健康供者外周血单核细胞(n=14)与糖皮质激素、RU486、甲氨蝶呤和生物制剂共培养。
  • 采用流式细胞术分析免疫亚群上LAG-3和PD-1的表达。

主要发现

  • 在PsA中,糖皮质激素抑制滑液单核细胞生长[2.3 (0.4) × 105 vs 培养基5.3 (0.7) × 105,P < 0.01],并显著上调CD14+LAG-3+细胞[11.7 (2.4)% vs 0.8 (0.3)%,P < 0.0001],但不影响CD3+LAG-3+和CD14+PD-1+细胞。
  • 甲氨蝶呤对CD14+LAG-3+细胞无影响[0.7 (0.3)%]。
  • 英夫利西单抗和依那西普相比培养基上调CD14+LAG-3+细胞[2.0 (0.6)%和1.6 (0.4)% vs 0.5 (0.1)%,P < 0.03],而IL-12/23抑制剂无此作用。
  • 在PsA和RA中,糖皮质激素对滑液单核细胞生长的抑制与CD14+LAG-3+细胞上调相关(r = 0.53,P = 0.03)。
  • RU486相比单用糖皮质激素剂量依赖性抑制糖皮质激素诱导的CD14+LAG-3+细胞上调[5 µM 5.3 (1.2)%和50 µM 1.3 (0.5)% vs 7.0 (1.4)%,P < 0.003],但对英夫利西单抗共培养的CD14+LAG-3+细胞无显著影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the impact of glucocorticoids (GCs) and anti-rheumatic drugs on lymphocyte activation gene-3 (LAG-3) and on programmed cell death-1 (PD-1) expression by synovial and peripheral cells ex vivo. METHODS: Synovial fluid mononuclear cells (SFMCs) from psoriatic arthritis (PsA, n = 26) and rheumatoid arthritis (RA, n = 13) patients, synovial fluid cells (SFCs) from osteoarthritis (OA, n = 5) patients and peripheral blood mononuclear cells (PBMCs) of healthy donors (n = 14) were co-cultured with GCs, glucocorticoid receptor antagonist RU486, methotrexate (MTX) and biologics. LAG-3 and PD-1 expression on immune subsets were analysed by flow cytometry. RESULTS: GCs in PsA inhibited SFMC growth vs medium [2.3 (0.4) × 105vs 5.3 (0.7) × 105, respectively, P < 0.01] and markedly up-regulated CD14+LAG-3+ cells [11.7 (2.4)% vs 0.8 (0.3)%, P < 0.0001, respectively], but not CD3+LAG-3+ and CD14+PD-1+ cells. MTX had no effect on CD14+LAG-3+ cells [0.7 (0.3)%]. The TNF inhibitors infliximab (IFX) and etanercept, but not IL-12/23 inhibitor, up-regulated CD14+LAG-3+ cells vs medium [2.0 (0.6)% and 1.6 (0.4)% vs 0.5 (0.1)%, P < 0.03, respectively]. SFMC growth inhibition by GC in both PsA and RA correlated with CD14+LAG-3+ cell up-regulation (r = 0.53, P = 0.03). RU486 inhibited GC-induced CD14+LAG-3+ cells up-regulation in a dose-dependent manner compared with GC alone [5 µM 5.3 (1.2)% and 50 µM 1.3 (0.5)% vs 7.0 (1.4)%, P < 0.003], but had no significant effect on CD14+LAG-3+ cells co-cultured with IFX. GCs in healthy donors' PBMCs up-regulated the immune subsets CD3+LAG-3+, CD14+LAG-3+ and CD14+PD-1+ cells. CONCLUSION: This study proposes a novel regulatory mechanism of GCs and of TNF inhibitors mediated by LAG-3 up-regulation in synovial cells and PBMCs. LAG-3 modulation may be a promising target for development of novel therapies for inflammatory arthritis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Gertel S, Polachek A, Eviatar T, et al. A novel inhibitory pathway of synovial inflammation exerted by glucocorticoids and tumour necrosis factor inhibitors via lymphocyte activation gene-3 up-regulation: an ex vivo study. Rheumatology (Oxford). 2025. PMID: 39052869. doi:10.1093/rheumatology/keae389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。